KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Inventory (2021 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Inventory for 5 consecutive years, with $44.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Inventory rose 15.7% year-over-year to $44.8 million, compared with a TTM value of $44.8 million through Sep 2025, up 15.7%, and an annual FY2024 reading of $39.2 million, down 1.2% over the prior year.
  • Inventory was $44.8 million for Q3 2025 at Aurinia Pharmaceuticals, up from $39.2 million in the prior quarter.
  • Across five years, Inventory topped out at $44.8 million in Q3 2025 and bottomed at $15.9 million in Q1 2021.
  • Average Inventory over 5 years is $30.2 million, with a median of $31.7 million recorded in 2023.
  • The sharpest move saw Inventory soared 64.82% in 2022, then fell 1.2% in 2024.
  • Year by year, Inventory stood at $19.3 million in 2021, then grew by 28.08% to $24.8 million in 2022, then surged by 60.41% to $39.7 million in 2023, then decreased by 1.2% to $39.2 million in 2024, then increased by 14.19% to $44.8 million in 2025.
  • Business Quant data shows Inventory for AUPH at $44.8 million in Q3 2025, $39.2 million in Q4 2024, and $38.7 million in Q3 2024.